OptimaCure

Company Overview

Snapshot

Founded in August 2013, OptimaCure operated with 1–10 employees. The company ceased operations in January 2019.

Business overview

OptimaCure specialized in providing personalized treatment solutions for cancer patients by repurposing failed cancer drugs. The company's core technology involved multiple robust screening approaches to identify optimal drug combinations for individual patients, enhancing the understanding of drug mechanisms through a combination of in vivo, in vitro, and in silico methods. OptimaCure aimed to identify patients most likely to respond to suggested treatments and broaden the application of repositioned cancer drugs, operating within the Health Tech & Life Sciences sector, specifically focusing on oncology, drug design, and personalized medicine.

Company Intelligence Q&A

What is OptimaCure's primary focus?

OptimaCure focuses on personalized cancer treatment by repositioning failed cancer drugs, identifying optimal drug combinations for individual patients.

When was OptimaCure founded?

OptimaCure was founded in August 2013.

What is OptimaCure's operational status?

OptimaCure is non-active and ceased to operate in January 2019.

What technology does OptimaCure utilize for drug repositioning?

OptimaCure employs a proprietary approach combining in vivo, in vitro, and in silico technologies to understand drug mechanisms and reposition them for appropriate cancer patients.

What markets does OptimaCure target?

OptimaCure's solutions are applicable globally, serving the healthcare and life sciences sectors with a focus on providers.